Few to no products in early development or testing.
Plavix situation still not resolved--if ruling fails to fall in Bristol-Myers Squibb's (and partner Sanofi-Aventis's) favor, sales and stock price will drop dramatically.
BMY could come back in 2013-2014.
But the technicals are not good, and if they are not good, it's probably because BMY is probably not that cheap.
Too many eyes are on it, it can't pretend to be a "hidden gem".
Proportionally lower R&D spending than many competitors.